Biotest AG
Biotest AG: Takeover Offer: Chinese strategic investor Creat to make a voluntary public takeover offer for the shares of Biotest AG
Biotest AG / Key word(s): Merger / Dreieich, 7 April 2017. Biotest AG, Tiancheng International Investment Limited, Hong Kong, and Blitz 17-623 AG (in future: Tiancheng (Germany) Pharmaceutical Holdings AG), affiliated companies controlled by Creat Group Corporation, have signed a Business Combination Agreement today. Tiancheng (Germany) Pharmaceutical Holdings AG announced today its decision to make a voluntary public takeover offer for all outstanding ordinary and preference shares of Biotest AG for EUR 28.50 per ordinary share and EUR 19.00 per preference share in an all-cash transaction. Subject to the terms and conditions of the Business Combination Agreement and their statutory fiduciary duties, in particular the review of the offer document to be published by Tiancheng (Germany) Pharmaceutical Holdings AG, Biotest AG’s Management Board and Supervisory Board welcome and support the voluntary takeover offer. The offer will be subject to a minimum acceptance threshold of 75 percent of all ordinary shares as well as regulatory approvals. Biotest AG has been informed that Biotest AG’s majority shareholder, OGEL GmbH, supports the transaction and has agreed with Tiancheng International Investment Limited, Hong Kong, to irrevocably accept the offer and to tender its shares, which represent 50.61 percent of all outstanding ordinary shares. The Management Board and the Supervisory Board of Biotest AG will provide a statement concerning this offer pursuant to their statutory duties upon publication of the offer document. Biotest Aktiengesellschaft Biotest AG Disclaimer IR contact Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201 Contact: Dr. Michael Ramroth Chief Financial Officer Biotest AG Landsteinerstr. 3 63303 Dreieich Tel. +40 6103 801 338 Fax: +49 6103 801 347 Michael.ramroth@biotest.com Information and Explanation of the Issuer to this News:
07-Apr-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | Biotest AG |
Landsteinerstraße 5 | |
63303 Dreieich | |
Germany | |
Phone: | 0 61 03 – 8 01-0 |
Fax: | 0 61 03 – 8 01-150 |
E-mail: | investor_relations@biotest.de |
Internet: | http://www.biotest.de |
ISIN: | DE0005227235, DE0005227201 |
WKN: | 522723, 522720 |
Indices: | SDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
End of Announcement | DGAP News Service |